Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.37 |
| ▸ | FAP | Q12884 | 3/20 | 0.37 |
| ▸ | NMT1 | P30419 | 5/20 | 0.34 |
| ▸ | NMT2 | O60551 | 4/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23986272 | 0.87 | ACE (0.33) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23986731 | 0.87 | ACE (0.33) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23810140 | 0.87 | ACE (0.38) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL26854776 | 0.86 | HRH3 (0.35) | — | |
| SCHEMBL24327205 | 0.85 | ACE (0.37) | DPP4 | |
| SCHEMBL25510029 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23766218 | 0.84 | ITGB3 (0.34) | ITGB3ITGA2B | |
| SCHEMBL24047853 | 0.82 | ELANE (0.37) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL22105668 | 0.82 | DPP7 (0.33) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL18754696 | 0.80 | DPP4 (0.35) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021018118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | WO | disclosed |